Glad I've loaded more CELZ shares. Whales are quietly accumulating because fair value is @ Dollar Land! The company is pursuing BIG Things. Fortunes will me made here. The fools who shorted CELZ shares will pay big time. Total shorted volume is over 106.95 Million with an average short volume is 5.35 Million. Huge Short Squeeze is imminent. Shorts are gonna be scrambling, weeping and biting their nails. https://marketwirenews.com/stock/celz/short/ Let's go CELZ to $1++ !!
KNOW WHAT YOU OWN
Internationally Renowned Clinician Scientist Camillo Ricordi Head of Diabetes Research Institute Joins Creative Medical Technology Holdings, Thursday, May 20, 2021, 8:45 AM ET
Immunologist Surgeon who Invented Islet Transplantation to Assist Company in Advancing ImmCelz(R) Platform
PHOENIX, May 20, 2021 /PRNewswire/ -- Creative Medical Technology Holdings announced today recruitment of Dr. Camillo Ricordi to the Company's Scientific Advisory Board. Dr. Ricordi will collaborate with Company Advisors such as Drs Timothy Henry, Santosh Kesari, Ceagan Du, and Boris Reznik in accelerating advancement of its ImmCelz(R) Regenerative Immunotherapy platform. Currently the Company is engaged with the FDA regarding clearance of its IND # 27375 covering the use of ImmCelz(R) to treat stroke.
"I have been following the work of Creative Medical Technology Holdings for many years as they evolved from a series of patents and a business plan to a clinical stage regenerative medicine company which already has proof-of-commercialization for its urology product." Said Dr. Camillo Ricordi. "The ImmCelz(R) Platform, to my knowledge, is a first-in-class approach to leveraging the immune system to act in a regenerative manner to treat a wide variety of indications including diabetes, liver failure, heart failure, and stroke."
The Company was the first to successfully develop a stem cell-based therapy for drug non-responsive erectile dysfunction which demonstrated efficacy in a clinical trial(1) . The CaverStem(R) Procedure is currently on the market through qualified physicians. Additionally, the Company has demonstrated clinical proof of concept of its patented StemSpine(R) Procedure for the treatment of degenerative disc disease and is currently in preclinical studies for its patented OvaStem(R) treatment for premature ovarian failure.
"We are honored to have Dr. Camillo Ricordi, a true translational medicine champion, join our team in utilizing regenerative medicine to provide hope in areas of medicine which currently have no hope." Said Timothy Warbington, President and CEO of the Company. "Dr. Ricordi's aggressive patient first approach is seen in his successes in treatment of numerous diseases in addition to diabetes which include COVID-19 and transplantation. Dr. Ricordi is a true Renaissance Man and we are eager to start our work with him."
Camillo Ricordi, MD, FNAI, is Professor and Director of the Diabetes Research Institute and the Cell Transplant Center at the University of Miami, Florida. He is inventor of the method to isolate insulin-producing cells from the pancreas, which led to successful transplantation to reverse diabetes. The procedure is now used worldwide. Dr. Ricordi's research interests include reversal of autoimmunity transplant tolerance, modulation of inflammation and regenerative medicine to prevent disease, and to prolong healthy lifespan. In 2020 he lead the international team that successfully completed the first FDA approved controlled trial to treat the most severe cases of COVID-19 with stem cell infusions. The unprecedented results allowed for 100% patient survival at one month in subjects treated who were less than 85 years old, compared to 42% survival in the control group. He received the Outstanding Scientific Achievement Award by the American Diabetes Association and was Knighted in the Order of Merit of the Italian Republic by the President of the Republic. In 2018 Dr. Ricordi was inducted into the National Academy of Inventors and was appointed to the Italian Supreme Council of Health (Consiglio Superiore di Sanita').
*** FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz(R) IND for Stroke Treatment, Friday, May 14, 2021, 7:45 AM ET
FDA Responds to Company's IND #27375 Including Pharmacology, Manufacturing and Clinical Sections
PHOENIX, May 14, 2021 /PRNewswire/ -- Creative Medical Technology Holdings Inc., trading under ticker symbol CELZ, announced today receipt of detailed correspondence from the FDA regarding necessary modifications to IND #27375 for using ImmCelz(R) regenerative immunotherapy for the treatment of stroke.
The Company's ImmCelz(R) product utilizes a patient's own blood cells that have been "reprogrammed" in the laboratory by culturing with established universal donor stem cells, followed by re-infusion into the patient. Efficacy in animal models has been demonstrated in heart failure, kidney failure, multiple sclerosis, liver failure and type 1 diabetes. Given that this is the first time such a product was brought to the FDA, the Company appreciates the detailed analysis provided by the Agency, and the constructive feedback.
"I am grateful for our scientific and clinical team which has assembled the ImmCelz(R) IND proposal for the FDA, which resulted in detailed comments and advice for moving forward. Our team is already working on it." said Timothy Warbington, President and CEO.
*** Creative Medical Technology Holdings, Inc. to Launch Virtual Physician(TM) Focused on Telehealth Solutions for Regenerative Medicine
PHOENIX, March 23, 2021 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced its intent to launch Virtual Physician(TM) focused on telehealth solutions for regenerative medicine this summer.
The company will initially utilize the platform to educate, recruit and retain patients for their already commercialized proprietary procedures in partnership with their national network of providers:
-- CaverStem(R): Regenerative Stem Cell Procedure for Treatment of Erectile
Dysfunction in Men
-- FemCelz(R): Regenerative Stem Cell Procedure for Vaginal Rejuvenation
As additional products are commercialized, (i.e. StemSpine(R) - Regenerative Stem Cell Procedure for Treatment of Degenerative Disc Disease), the platform will expand to include these products.
Furthermore, the company plans to build out Virtual Physician(TM) to include additional products outside of their proprietary procedures focused on regenerative medicine. "While our primary interest is in supporting our providers and to educate, recruit and retain patients for our proprietary procedures through this innovative platform, we are also aware of the power of telehealth to accelerate acceptance for regenerative medicine more broadly", said Timothy Warbington, President and CEO of Creative Medical Technology Holdings Inc. "While several telehealth companies have emerged (i.e. Teladoc with market cap of $29B; HIMS & HERS Health with market cap of $2.5B), none address this area of breakthrough medicine. As a company at the forefront of this cutting-edge industry, we see it as our responsibility to drive broad adoption."
Virtual Physician creates three unique opportunities to drive shareholder value:
-- Management Service Organization (MSO): Charging a fee per qualified
patient to providers -- conversations with existing providers validates
this as highly valuable
-- Royalty for promotion of products from external partners: As the platform
grows in popularity, company can charge a fee from other manufacturers
for featuring their products
-- Direct sales of ancillary products to consumers on platform: Become a
one-stop shop for our patients by curating and consolidating additional
products to improve underlying medical conditions
*** Creative Medical Technology Holdings, Inc. Announces FDA Acknowledgment of IND Application for ImmCelz(R) to Treat Stroke
Tuesday, March 16, 2021, 7:15 AM ET
PHOENIX, March 16, 2021 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced that the FDA issued IND Number 27375 to the Company in connection with its Clinical Trial application to use ImmCelz(R) to treat stroke victims.
The ImmCelz(R) treatment involves utilization of stem cells outside of the body to "reprogram" the patient's own immune cells so as to endow the immune cells with regenerative properties. In contrast to other stem cell based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissue and induce regeneration.
"This is a major milestone for the Company," exclaimed Timothy Warbington, President and CEO of the Company. "We look forward to hearing back from the FDA and moving ImmCelz(R) rapidly to the clinic."
*** Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine(R) Personalized Adult Stem Cell Therapy
Commercial Stage Regenerative Medicine Company Expands it's Hold "Ready to Commercialize" Autologous Bone Marrow Procedures
PHOENIX, March 4, 2021 /PRNewswire/ -- (OTC - CELZ) Creative Medical Technology Holdings announced today a publication in the pre-print server SSRN describing data from its first 15 patients treated in a clinical trial evaluation perispinal injection of bone marrow cells in patients with disc degenerative disease. Evaluation of patients at 30,60 90, 180, and 360 days revealed significant improvement in mobility and reduction in pain score . The mean pain changed from 8.9 at baseline to 4.3 at 30 days and sustained to 1.8 at 6 months and 1.3 at 12 months with a gradual reduction in overall pain medication utilization guided by their healthcare team. No serious adverse effects were noted with some short-term bruising in two patients at the harvest site and no long term adverse events where reported related to the procedure.
"This publication, which is "pre-peer review" describes what to our knowledge is the first demonstration of a signal of clinical efficacy by injecting stem cells in areas surrounding the disc." Said Dr Amit Patel, Board Member and Co-Founder of the Company. "While others have intra-disc injection may help disc pain, the current work regenerates the blood supple to the disc, allowing the disc to heal itself."
The autologous utilization of bone marrow falls under the "minimal manipulation exception" and can be commercialized rapidly, in the same manner that the Company commercialized Caverstem(R) for treatment of erectile dysfunction.
Granted United States Patent #9,598,673 which is owned by the Company covers the use of any mesenchymal stem cells, both from the patient or from donors, for reduction of lower back pain when injected into the major muscles of the lower back.
"Disc degenerative disease represents a multi-billion dollar market for which current medical solutions do not address the underlying cause, while surgery is expensive and not applicable for a significant number of patients." Said Timothy Warbington, President and CEO of the Company. "We are excited to follow the path we did with CaverStem(R) and initiate commercialization of this technology for American patients."
To view our Publication: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3797402
*** Creative Medical Technology Holdings Provides Update on ImmCelz(R) FDA Application, March 3, 2021
***Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented OvaStem(R) Female Infertility/Ovarian Failure Treatment, Feb 10, 2021
***Creative Medical Technology Holdings Recruits Internationally Renowned Kidney Expert to Scientific Advisory Board, Feb 8, 2021
***Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz(R) Therapeutic Activity, Monday, February 1, 2021
Company Demonstrates that in Addition to Activating Endogenous Stem Cells and T Regulatory Cells ImmCelz(R) Induces Surge of Therapeutic Protein HGF-1, Feb 1, 2021
***Creative Medical Technology Holdings Files Patent based on Positive Data on Renal Failure using ImmCelz(R) Regenerative Immunotherapy
Wednesday, January 27, 2021, 7:45 AM ET
*** Creative Medical Technology Holdings Recruits Founder of Inc 500 Clinical Trials Company Dr. Boris Reznik to Accelerate Development of ImmCelz(R) Through FDA, Thursday, January 21, 2021
*** Creative Medical Technology Holdings Announces Patent filing based on Preclinical Data in Model of Heart Attack using ImmCelz(R) Regenerative Immunotherapy!!
*** CELZ Files Patent on Approaching 10 Billion Dollar Liver Disease Market Using "Reprogrammed" Immune Cells
*** Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz(R) Personalized Cellular Immunotherapy in Preclinical Model